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In a strategy aimed at identifying novel markers of human prostate cancer, we performed expression analysis using microarrays of
clones randomly selected from a cDNA library prepared from the LNCaP prostate cancer cell line. Comparisons of expression
profiles in primary human prostate cancer, adjacent normal prostate tissue, and a selection of other (nonprostate) normal human
tissues, led to the identification of a set of clones that were judged as the best candidate markers of normal and/or malignant prostate
tissue. DNA sequencing of the selected clones revealed that they included 10 genes that had previously been established as prostate
markers: NKX3.1, KLK2, KLK3 (PSA), FOLH1 (PSMA), STEAP2, PSGR, PRAC, RDH11, Prostein and FASN. Following analysis of the
expression patterns of all selected and sequenced genes through interrogation of SAGE databases, a further three genes from our
clone set, HOXB13, SPON2 and NCAM2, emerged as additional candidate markers of human prostate cancer. Quantitative RT–PCR
demonstrated the specificity of expression of HOXB13 in prostate tissue and revealed its ubiquitous expression in a series of 37
primary prostate cancers and 20 normal prostates. These results demonstrate the utility of this expression-microarray approach in
hunting for new markers of individual human cancer types.
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Prostate cancer is a heterogeneous disease with respect to its
behaviour and response to hormonal therapy. While some early
cancers would be expected to progress rapidly, many cases remain
dormant for many years or even decades. A rise in blood PSA level
is used widely to detect prostate cancer, but PSA is also elevated in
men with chronic prostatitis or benign prostatic hyperplasia
(BPH), thus leading to a decrease in the specificity of this marker.
Additionally, blood PSA is not significantly increased in some
early prostate cancers, particularly those that are poorly differ-
entiated and hence likely to be aggressive. New clinical markers are
necessary both to improve specificity of detection and to predict
the clinical behaviour of early disease.
Microarray technology has been used to aid the search for new
diagnostic and prognostic markers for prostate cancer (Dhanase-
karan et al, 2001; Luo et al, 2001 ,2002; Magee et al, 2001; Stamey
et al, 2001; Welsh et al, 2001; Ernst et al, 2002; LaTulippe et al,
2002; Singh et al, 2002) (reviewed in Kumar-Sinha et al, 2003).
These studies have utilised both cDNA and oligonucleotide
technologies to examine expression profiles in normal prostate,
BPH, prostate cancer and in some cases metastatic hormone-
refractory prostatic disease. Previously established markers of
prostate cancer such as KLK2, KLK3 (PSA) and FOLH1 (PSMA)
were commonly highlighted and an additional cohort of genes
consistently upregulated in prostate cancer emerged including
Hepsin, AMACR and FASN. Meta-analysis of several of these
studies (Rhodes et al, 2002) additionally revealed altered
transcription of many genes involved in polyamine and purine
biosynthesis pathways in prostate cancer. Expression-microarray
studies have also identified EZH2 as a gene overexpressed in
hormone-refractory metastatic prostate cancer: notably, patients
with clinically localised prostate cancer (Varambally et al, 2002)
that express EZH2 have a worse prognosis than those that do not
express the protein.
In the present study, we have performed expression studies
using microarrays of clones randomly selected from cDNA
libraries prepared from the LNCaP prostate cancer cell line. The
use of a microarray of randomly chosen clones is a crucial first
step of selection because the clone set should be enriched in genes
overexpressed in prostate cancer. This strategy identified many
genes previously confirmed to represent markers of human
prostate tissue and highlighted several additional potential
markers of this disease, including HOXB13, and also offers the
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MATERIALS AND METHODS
Cell lines, tissue procurement and RNA preparation
The LNCaP and PC-3 prostate cancer cell lines and PNT2, an
immortalised prostate epithelial cell line, were kindly provided by
Professor Norman Maitland and grown in the recommended
culture conditions. Total RNA was prepared from these cell lines as
described (Wilkinson, 1988). Fresh prostate adenocarcinoma
specimens were obtained from men undergoing prostatectomy.
Sections from these specimens were used in H&E staining studies
to assess the relative proportions of tumour, non-neoplastic
epithelium and stroma. Regions of the specimen rich in tumour
cells or in non-neoplastic epithelium were selected and preserved
in RNAlater
s (Ambion, Huntingdon, UK). All tumour specimens
chosen for the microarray study were Gleason grade 7 (3þ4o r
4þ3). Of the additional tumour specimens selected for quantita-
tive PCR analysis (13 TURP, 13 radical prostatectomy), 14 were
poorly, 11 moderately and one well differentiated. A further six
normal tissues from prostatectomies were also used. RNA from
these specimens was prepared using TRIzol
s reagent (Invitrogen,
Paisley, UK) according to the manufacturer’s guidelines with the
additional step of a second chloroform extraction before
precipitation. RNA from normal prostate and other normal human
tissues were obtained from BD Biosciences (Oxford, UK), Ambion
(Huntingdon, UK) and Stratagene (La Jolla, CA, USA). The
Northern blot was prepared as described before (Clark et al,
2002) and probed with the
32P-dCTP-labelled PCR-amplified
HOXB13 cDNA clone identified on the microarray.
cDNA microarrays
A cDNA library from the LNCaP prostate cancer cell line was made
using a cDNA synthesis kit (Stratagene, La Jolla, CA, USA) as
described previously (Clark et al, 2002). Library cDNA clones were
picked, grown and stored as described previously (Clark et al,
2002). DNA inserts from the picked clones were amplified by PCR
and microarrayed onto Gold Seal glass slides (Merck Eurolab Ltd,
Poole, UK) coated with poly-L-lysine as described previously
(Clark et al, 2002). Sample labelling, microarray hybridisation,
data collection and data analyses were also carried out as described
previously (Clark et al, 2002). Hybridisations were performed in
triplicate and the results averaged for each clone.
Ranking of overexpressed genes
To grade the significance in the differences of microarray features
between two groups, we initially calculated the ratio of means and
applied the Student’s t-test (Rees, 2001). Two additional tests that
are influenced by both the magnitudes and variations of individual
features were also applied. These were the Fisher F¼(m1 m2)
2/
(s1
2þs2
2) and Golub G¼|m1 m2|/(s1 s2) score, where mi and si are
the mean and standard deviation for features belonging to class i.
In addition to grade features according to the consistency of a
difference, the rank-based Mann–Whitney test and the Threshold
Number of Misclassifications (TNoM) test were applied (Ben Dor
et al, 2000; Rees, 2001). For each of the six tests (ratio of means,
Student’s t-test, Mann–Whitney test, TNoM, Fisher score, Golub
score), clones with overexpressed patterns in one sample group
compared to those observed in a second sample group were ranked
according to biggest ratio, most significant difference or most
consistent differences. From the rankings derived from these six
statistical scores, we also derived an aggregate ranking score.
Given the different principles underlying the individual six scores,
this aggregate ranking is only loosely defined, but we found this
overall score informative (see Results).
SAGE expression analysis
To examine the breadth of tissue expression of genes represented
by the top 100 ranked clones, we mined the summary SAGE
expression data from the Cancer Gene Anatomy Project http://
cgap.nci. nih.gov/. This method presents the tissue expression level
for a representative gene tag sequence by summing the tags for
each library of a particular tissue type and normalising to tags/
200000 tags. The best tag for a particular gene was selected by the
criteria described http://cgap.nci.nih.gov/SAGE/SAGEHelp. Tissue
expression levels for each gene are then depicted by a coloured
scale as described http://cgap.nci.nih.gov/Microarray/MicroArray-
Help. These data also reveal ‘similarly expressed’ genes in the top
100 list as the rows are ordered by strength of correlation.
Quantitative PCR
cDNA was prepared using Superscriptt II (Invitrogen, Paisley,
UK) reverse transcriptase and a random primer (pdN6) according
to the manufacturer’s protocol. The overexpression of HOXB13
was verified using the TaqMan
s quantitative PCR system (Applied
Biosystems, Warrington, UK). The Assay-On-Demandt primer
and probe set Hs00197189_m1 (Applied Biosystems, Warrington,
UK) was used to specifically detect HOXB13 transcripts. A GAPDH
endogenous control reagent (Applied Biosystems) was used as a
reference in multiplexed PCR reactions, which were run on an ABI
PRISM
s 7900HT Sequence Detection System (Applied Biosys-
tems) using TaqMan
s Universal PCR Master Mix (Applied
Biosystems) with standard thermocycling conditions (501C 2min,
951C 10min, then 40 cycles of 951C1 5 s ,6 0 1C 1min). A
commercial normal prostate RNA from BD Biosciences was used
as the reference (calibrator) sample. The comparative threshold
cycle (CT) method was used for the calculation of fold over-
expression where relative amount¼2 DDCT, where  DDCT is the
normalised signal level (threshold cycle test gene threshold cycle
endogenous control (GAPDH)) in the sample relative to the
normalised signal level in the corresponding calibrator sample.
RESULTS
Microarray expression profiling
Expression studies were performed using microarrays of 5760
unidentified clones randomly selected from a cDNA library
prepared from the LNCaP prostate cancer cell line. In hybridisation
studies, 36% of the clones were identified as homologous to
mitochondrial sequences and these spots were removed from the
microarray electronically prior to data analysis. Microarray expres-
sion profiles were collected from 11 prostate cancers, from 10
adjacent regions of morphologically normal prostate and from 12
nonprostate normal tissues (bone marrow, brain, breast, thymus,
liver, kidney, skeletal muscle, thyroid, testis, bladder, colon and
lung). In each case, the test cDNA labelled with Cy5 was compared
to cDNA similarly labelled with Cy3 prepared from the immortalised
epithelial prostate cell line PNT2 (Berthon et al,1 9 9 5 ) .
Identification of prostate markers
We first compared the expression of cDNA clones in the 11
prostate cancer samples to their expression in a series of 12
nonprostate normal tissues using the following mathematical tests:
ratio of means, Student’s t-test, Mann–Whitney test, TNoM test,
Fisher score and Golub score. The sum of the rankings obtained by
each of these tests were then used as a metric to define the overall
rank of overexpression for each clone in prostate cancer compared
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subject to DNA sequencing to reveal their identities (Supplemen-
tary Table 1 http://www.icr.ac.uk/array/array.html). Notably, these
clones included many genes previously proposed as prostate
markers KLK3 (PSA), PRAC, STEAP2 and RDH11 (Table 1,
Figure 1).
The same approach was used to derive a metric that compared
expression in the series of 11 samples of morphologically normal
prostate tissue collected from regions adjacent to prostate cancer
with the same series of 12 nonprostate normal tissues. In all, 20 of
the genes previously sequenced were also present in this top 100
list of overexpressed clones (Supplementary Table 2 http://
www.icr.ac.uk/array/array.html). The list also included three
additional genes, KLK2, PSGR (OR51E2) and Prostein, that have
previously been established as prostate markers.
The metric was also used to rank the overexpression of clones in
10 prostate cancers compared to the 11 samples of adjacent normal
prostate tissue. The top 100 list of overexpressed clones
(Supplementary Table 3 http://www.icr.ac.uk/array/array.html)
showed a small overlap (six genes) with both the previous two
top 100 lists and included two further recognised markers of
prostate cancer: FASN and FOLH1 (PSMA).
These analyses have highlighted a total of 10 recognised prostate
cancer markers, thus providing a strong validation of our
approach.
Novel candidate prostate markers
To further assess the tissue and tumour specificity of genes in our
three top 100 candidate lists, we interrogated SAGE databases for
the genes where suitable SAGE tags could be identified. These
studies revealed a set of 10 genes that appeared to have higher
levels of gene expression in normal and malignant prostate
compared to most other normal and cancerous tissue (Figure 2).
Other genes in the top 100 lists (Supplementary Tables 1–3) did
not appear to exhibit the same specificity for expression in the
prostate when subject to SAGE analysis. The list of 10 genes again
included the well-established prostate cancer markers KLK2, KLK3
(PSA), FOLH1 (PSMA), PSGR (OR51E2), STEAP2, NKX3.1 and
Prostein), and also included NCAM2, SPON2 and HOXB13.
NCAM2, SPON2 and HOXB13 as markers of human
prostate cancer
NCAM2 is a close homologue of the neural cell adhesion molecule
NCAM1. The gene is known to be expressed at high levels in the
brain and at low levels in a variety of other adult tissues including
the testis, heart and lung (Paoloni-Giacobino et al, 1997). SPON2
was originally isolated as a gene downregulated in lung cancer cell
lines compared to normal lung (Manda et al, 1999). Initial
quantitative RT–PCR experiments (results not shown) demon-
strated a highly variable level of expression in prostate cancer with
low levels in a range of normal tissue as follows: the thymus,
thyroid, breast, colon, liver, lung and bladder. These two genes
were not studied further.
HOXB13 was present in the top 100 gene lists for all three
microarray-based comparisons that we had performed (Supple-
mentary Tables 1–3) and statistical analysis of the microarray data
demonstrated that the values in prostate cancer were significantly
higher than those found in normal adjacent prostate (Student’s t-
test, Po0.001). SAGE database searches indicated that HOXB13
was expressed in at least two individual primary prostate samples
(http://cgap.nci.nih.gov). To establish experimentally that the
HOXB13 gene is specifically upregulated in malignant and normal
prostate cancer, we used quantitative RT–PCR to assess levels of
HOXB13 transcripts in 37 primary prostate cancer specimens, 16
samples of adjacent normal prostate, four samples of normal
prostate from individuals who did not have prostate cancer and 12
nonprostate normal tissues. Our results show that HOXB13
transcripts could be detected in all specimens of prostate cancer
and in most cases at levels comparable or above those found in
normal prostate (Figure 3). Analyses of normal human tissue
confirmed that high levels of expression of HOXB13 is restricted to
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Figure 1 Genes overexpressed in prostate cancer compared to
nonprostate normal tissue. We used microarrays of cDNA clones
randomly selected from an LNCaP library to identify genes that were
overexpressed in a series of 11 prostate cancer samples compared to a
series of 12 nonprostate normal tissues. The top 100 ranked over-
expressed clones were identified by DNA sequencing. The figure shows a
heat map of the expression patterns of the top 50 ranked clones. The full
list of 100 clones is available as Supplementary Table 1 (http://
www.icr.ac.uk/array/array.html). The red typeface flags genes that have
previously been identified as prostate markers.
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Figure 2 Breadth of gene expression. Gene expression was determined by mining SAGE expression data from the Cancer Genome Anatomy Project
(http://cgap.nci.nih.gov). Tissue expression levels for each gene are depicted by a coloured scale as described http://cgap.nci.nih.gov/Microarray/
MicroArrayHelp. The figure shows a group of 10 genes that appear to be highly expressed in the prostate in relation to other cancers and tissues.
Table 1 Identification of known prostate-associated genes in microarray-based expression studies
Unigene ID (build #170) Locus
Cancer vs tissues
(highest rank
a)
Normal vs tissues
(highest rank
a)
Cancer vs normal
(highest rank
a) Reference
Hs.278695 Prostein 18 Xu et al (2001)
Hs.181350 KLK2 54 Darson et al (1997)
Hs.55999 NKX3.1 5 Gelmann et al (2003)
Hs.83190 FASN 6 Welsh et al (2001)
Hs.1915 FOLH1 67 Burger et al (2002)
Hs.408200 STEAP2 1 31 4 Korkmaz et al (2002)
Hs.116467 PRAC 26 78 Liu et al (2001)
Hs.171995 KLK3 57 3 Stamey et al (1987)
Hs.226007 RDH11 32 4 Lin et al (2001)
Hs.202300 PSGR
(OR51E2)
19 Xu et al (2000)
aAggregate ranking calculated as described in the Materials and Methods.
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Figure 3 HOXB13 expression in human tissues. HOXB13 expression levels were determined by quantitative RT–PCR in a series of 37 primary prostate
cancers (PT), 16 samples of morphologically normal prostate tissue taken adjacent to prostate cancer (ANP), four normal prostate samples from individuals
who did not have prostate cancer (NP), two prostate cancer cell lines and a selection of nonprostate normal tissues. All amounts are expressed in relation to
the levels found in normal prostate sample 3 (NP3). *Samples used in microarray experiments. The inset shows a Northern blot of two independent
extractions of PC3 RNA probed with an HOXB13 cDNA clone confirming the expression of two HOXB13 transcripts (2 and 4kbp) in this cell line.
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DISCUSSION
In a previous study, we have demonstrated that comparative
genomic hybridisation and expression studies onto microarrays of
clones randomly selected from tumour cell lines containing DNA
amplicons are an effective method for identifying candidate
amplified and overexpressed genes (Clark et al, 2002). In the
current study, we have shown that expression studies alone onto
microarrays of clones randomly selected from cancer cDNA
libraries can also be used to identify tumour markers. The
particular design used in this study should enrich the microarray
with genes overexpressed in prostate cancer and help avoid
exclusion of important genes that can occur in microarrays of
preselected genes. Our distinct expression-microarray approach
was validated since it identified 10 genes that had previously been
established experimentally as prostate markers: NKX3.1, KLK2,
KLK3 (PSA), PSGR, FOLH1 (PSMA), STEAP2, PRAC, RDH11,
Prostein and FASN. It is possible that additional markers could
have been identified if the number of clones selected from the
LNCaP cDNA library had been enlarged. For example, the prostate
cancer markers Hepsin and AMACR are both reported to be
expressed in LNCaP cells (Kuefer et al, 2002; Srikantan et al, 2002)
but were not detected as markers in our studies on 5760 clones
randomly selected from an LNCaP cDNA library. When our lists of
candidate markers were combined with searches of SAGE
databases, HOXB13 emerged as a candidate prostate marker.
SAGE database searches indicated that HOXB13 was expressed in
at least two individual primary human prostate samples and in
quantitative RT–PCR studies we have experimentally demon-
strated for the first time the ubiquitous expression of HOXB13 in
human prostate tissue.
Interestingly HOXB13 is located at chromosome band 17q21
immediately adjacent to the PRAC and PRAC2 genes, which have
also been proposed as markers of human prostate cancer (Liu et al,
2001; Olsson et al, 2003). It is well established from studies in
several eukaryotic species including Drosophilia and man that gene
expression can be coordinated in domains and the PRAC-PRAC2-
HOXB13 gene cluster may represent a chromosomal domain
specifically expressed in prostate.
It is well established that HOXB13 paralogues are important in
prostate development in mice. HOXA13 and HOXD13 have roles in
the patterning and outgrowth of lobes of the mouse prostate gland
(Kondo et al, 1997; Podlasek et al, 1997, 1999; Warot et al, 1997)
and HOXB13 is required for the normal differential and secretory
function of mouse prostate (Economides and Capecchi, 2003).
HOXB13 was reported to be expressed only in the prostate and
colon of mice in an androgen-independent manner (Sreenath et al,
1999) consistent with our expression studies in normal human
tissues.
Unlike the human prostate, mouse prostate is divided into four
distinct lobes (ventral, dorsal, lateral and anterior). Transgenic
mouse studies suggest that expression and function of HOXB13 is
restricted to the mouse ventral prostate (Economides and
Capecchi, 2003) where it is involved in controlling secretion of
p12, a kazal-type protease inhibitor, and the spermine binding
protein p25. Notably, the rodent ventral prostate is not believed to
have a counterpart in man (Price, 1963). The observation that
HOXB13 is ubiquitously expressed both in normal and cancerous
human prostate could therefore indicate that the distribution of
expression of HOXB13 in mice and man may be distinct, or suggest
that the proposition that the ventral mouse prostate does not have
a counterpart in man is incorrect.
NKX3.1, another homeobox gene involved in the development
of mouse prostate, was also highlighted in our studies. NKX3.1,
unlike HOXB13, exhibits androgen-dependent expression (Bieber-
ich et al, 1996; Sciavolino et al, 1997) and is more broadly
expressed in the mouse prostate. NKX3.1 appears to have a
role in prostate cancer development since transgenic mice
that have homozygous mutations of the NKX3.1 gene (Bhatia-
Gaur et al, 1999; Abdulkadir et al, 2002) develop the
early cancerous lesion prostatic intraepithelial neoplasia (PIN).
Prostatic intraepithelial neoplasia development in these mice is
restricted to the anterior mouse prostate lobes and is not found
in the ventral prostate lobe. Transgenic mice containing homo-
zygous mutations of the HOXB13 gene, in contrast, do not appear
to be predisposed to prostate cancer development (Economides
and Capecchi, 2003). Based on these studies HOXB13 removal
would not be predicted to be involved in prostate cancer
development. Recent studies in which overexpression of HOXB13
was forced in prostate cancer PC3 cells did, however, indicate that
this homeodomain protein has the potential to act as a suppressor
of cell growth possibly through modulating the expression of TCF-
4 (Jung et al, 2004). These results, however, conflicted with those
obtained by Ma et al (2004), who found that HOXB13 enhances
mortality and invasion of breast epithelial cells and that the
HOXB13:IL17BR expression ratio was predictive of disease-free
survival.
In conclusion, we have demonstrated the effectiveness of this
expression microarray approach, which utilises microarrays of
randomly selected cDNA clones, for identifying markers of
individual cancer types. The approach has identified 10 established
prostate markers and has further highlighted the potential use of
HOXB13 as a diagnostic marker.
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